Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA.
Humans
Hispanic or Latino
/ statistics & numerical data
Mpox (monkeypox)
/ epidemiology
New York
/ epidemiology
Socioeconomic Factors
Race Factors
/ statistics & numerical data
White
/ statistics & numerical data
Black or African American
/ statistics & numerical data
Asian American Native Hawaiian and Pacific Islander
/ statistics & numerical data
Antiviral Agents
/ therapeutic use
New York
New York City
United States
emergencies
health equity
mpox
racism
sexually transmitted infections
tecovirimat
viruses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
medline:
1
11
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other). Future public health emergency responses must prioritize institutional and structural racism mitigation.
Identifiants
pubmed: 37796277
doi: 10.3201/eid2911.230814
pmc: PMC10617352
doi:
Substances chimiques
tecovirimat
F925RR824R
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2353-2357Références
JAMA Health Forum. 2022 Feb 4;3(2):e220548
pubmed: 36218834
N Engl J Med. 2022 Nov 10;387(19):1783-1793
pubmed: 36286263
MMWR Morb Mortal Wkly Rep. 2022 Oct 28;71(43):1359-1365
pubmed: 36301738
Lancet. 2017 Apr 8;389(10077):1453-1463
pubmed: 28402827
Am J Public Health. 2015 Feb;105(2):e75-82
pubmed: 25521875
MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1018-1022
pubmed: 35951487
N Engl J Med. 1994 Mar 17;330(11):763-8
pubmed: 8107743